ÌÇÐÄvlog´«Ã½

Peptide Synthesis Market Analysis

The Global Peptide Synthesis Market size is estimated at USD 0.89 billion in 2024, and is expected to reach USD 1.21 billion by 2029, growing at a CAGR of 6.35% during the forecast period (2024-2029).

Rising investments and substantial funding for genomics and proteomics research are driving the demand for peptides in drug discovery and therapeutic development. Owing to the rising demand for effective protein-based drugs for the proper treatment process, increasing investments, and significant funding for the research and development of genomics and proteomics in the biopharmaceutical industry, the market is expected to grow during the forecast period.

The increasing government funding to support research and developmental activities and drug discovery is expected to boost the growth of the market, as these investments drive the demand for peptides in genomics and proteomics research. According to the article published by the Department of Health and Aged Care, Australia, in March 2022, the Australian government invested USD 28.1 million from 2022-23 to 2025-26 to establish a new agency, Genomics Australia, to support the integration of genomic medicine as a standard of healthcare in Australia. Such investments by governments are also expected to propel market growth.

There is a rising demand for peptide synthesis as it is useful for proteomics-based biomarker discovery and validation on specific diseases, which is anticipated to boost the market’s growth. For instance, according to an article published by Nature Journal in June 2023, the preference for the PepQuant library over high-resolution mass spectrometry for human blood biomarker discovery expanded the utilization of peptide libraries. This contributes to the increasing research and developments concerning disease therapeutics that use peptides, thus contributing to the market's growth.

Advancements in peptide synthesizer technology, such as microwave-assisted SPPS (solid phase peptide synthesis), have significantly enhanced peptide production. These innovations offer faster synthesis times, increased automation, improved quality, greater scalability, real-time monitoring, and reduced solvent usage. These innovations can accelerate the development of new peptide-based therapeutics, making peptide synthesis more efficient and cost-effective.

The rising benefits of peptide synthesizers, such as their high efficiency and scalability, are anticipated to boost market growth. For instance, according to the study published in Nature Communications in December 2023, peptide synthesis was executed using a Liberty PRIME 2.0 automated microwave peptide synthesizer at a 0.1 mmol scale, incorporating one-pot coupling and deprotection steps. This peptide synthesizer resulted in a highly efficient, pure, and scalable process, reducing waste by up to 95% and requiring only 10-15% of the standard base amount. Therefore, the advantages of effectively conserving solvents with advanced peptide synthesizers are anticipated to increase the adoption of innovative equipment and drive market growth.

However, large-scale synthesis often encounters scalability issues, leading to production challenges and increased costs. Large-scale peptide synthesis demands huge capital, equipment, and skilled labor. A lack of skilled workforce can become a challenge and, hence, limit the growth of the market.

Peptide Synthesis Industry Segmentation

Peptides are a unique class of highly active and specific pharmaceutical compounds, molecularly poised between small molecules and proteins yet biochemically and therapeutically diverse from both. The advantages of peptides, such as relative ease of synthesis, ready availability, and low toxicity, increased their applications in the pharmaceutical, nutritional, and cosmetic industries, resulting in high demand for rapid advancements in the technologies to enhance their synthesis.

The peptide synthesis market is segmented by technology, product, end user, and geography. By technology, the market is segmented into solid-phase, liquid-phase, and hybrid and recombinant. By product, the market is segmented into equipment, reagents and consumables, and services. The reagents and consumables are further segmented into enzymes and others. By end user, the market is segmented into pharmaceutical and biotechnology companies, contract development and manufacturing organizations (CDMO), and academic and research institutes. By geography, the market is segmented into North America, Europe, Asia-Pacific, Latin America, and Middle East and Africa. The report also covers the market sizes and forecasts in 21 countries across major regions. For each segment, the market sizing and forecasts were made on the basis of revenue (USD).